Efficient and accurate classification of brain tumor categories remains a critical challenge in medical imaging. While existing techniques have made strides, their reliance on generic features often leads to suboptimal results. To overcome these issues, Multimodal Contrastive Domain Sharing Generative Adversarial Network for Improved Brain Tumor Classification Based on Efficient Invariant Feature Centric Growth Analysis (MCDS-GNN-IBTC-CGA) is proposed in this manuscript.Here, the input imagesare amassed from brain tumor dataset. Then the input images are preprocesssed using Range - Doppler Matched Filter (RDMF) for improving the quality of the image. Then Ternary Pattern and Discrete Wavelet Transforms (TPDWT) is employed for feature extraction and focusing on white, gray mass, edge correlation, and depth features. The proposed method leverages Multimodal Contrastive Domain Sharing Generative Adversarial Network (MCDS-GNN) to categorize brain tumor images into Glioma, Meningioma, and Pituitary tumors. Finally, Coati Optimization Algorithm (COA) optimizes MCDS-GNN's weight parameters. The proposed MCDS-GNN-IBTC-CGA is empirically evaluated utilizing accuracy, specificity, sensitivity, Precision, F1-score,Mean Square Error (MSE). Here, MCDS-GNN-IBTC-CGA attains 12.75%, 11.39%, 13.35%, 11.42% and 12.98% greater accuracy comparing to the existingstate-of-the-arts techniques, likeMRI brain tumor categorization utilizing parallel deep convolutional neural networks (PDCNN-BTC), attention-guided convolutional neural network for the categorization of braintumor (AGCNN-BTC), intelligent driven deep residual learning method for the categorization of braintumor (DCRN-BTC),fully convolutional neural networks method for the classification of braintumor (FCNN-BTC), Convolutional Neural Network and Multi-Layer Perceptron based brain tumor classification (CNN-MLP-BTC) respectively.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/15368378.2024.2375266 | DOI Listing |
J Thorac Oncol
January 2025
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:
Introduction: Treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with disease progression on/after osimertinib and platinum-based chemotherapy are limited.
Methods: CHRYSALIS-2 Cohort A evaluated amivantamab+lazertinib in patients with EGFR exon 19 deletion- or L858R-mutated NSCLC with disease progression on/after osimertinib and platinum-based chemotherapy. Primary endpoint was investigator-assessed objective response rate (ORR).
J Clin Neurosci
January 2025
Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; Department of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA. Electronic address:
Background: Glioblastoma (GBM) is a common brain tumor with a poor prognosis. There is a paucity of knowledge regarding optimal treatment approaches for elderly patients with GBM who have a relatively good Karnofsky (KPS) or Eastern Cooperative Oncology Group (ECOG) performance status. This study compared treatment outcomes in older patients (≥65) with GBM based on their performance status, either high (KPS ≥ 70 and ECOG < 2) or low (KPS < 70 and ECOG ≥ 2), who underwent hypofractionated radiotherapy (HFRT) (40 Gy in 15 fractions) versus conventional fractionation (60 Gy in 30 fractions).
View Article and Find Full Text PDFESMO Open
January 2025
Dana-Farber Cancer Institute, Boston. Electronic address:
Background: Brain metastases (BMs) are common in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, increasing morbidity and mortality. Systemic therapy for BMs can be effective, with the triple combination of trastuzumab, capecitabine, and tucatinib being a potential standard. More recently, intracranial activity of antibody-drug conjugates has been reported, but the size of individual studies has been small.
View Article and Find Full Text PDFCancer Commun (Lond)
January 2025
Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
ACS Nano
January 2025
Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
Glioblastoma multiforme (GBM), particularly the deep-seated tumor where surgical removal is not feasible, poses great challenges for clinical treatments due to complicated biological barriers and the risk of damaging healthy brain tissue. Here, we hierarchically engineer a self-adaptive nanoplatform (SAN) that overcomes delivery barriers by dynamically adjusting its structure, surface charge, particle size, and targeting moieties to precisely distinguish between tumor and parenchyma cells. We further devise a AN-uided ntuitive and recision ntervention (SGIPi) strategy which obviates the need for sophisticated facilities, skilled operations, and real-time magnetic resonance imaging (MRI) guidance required by current MRI-guided laser or ultrasound interventions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!